ContraVir Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CTRV)

$0.34 -0.01 (-1.45 %)
(As of 12/17/2017 04:00 PM ET)
Previous Close$0.34
Today's Range$0.34 - $0.36
52-Week Range$0.32 - $1.99
Volume569,833 shs
Average Volume929,926 shs
Market Capitalization$26.61 million
P/E RatioN/A
Dividend YieldN/A
Beta1.44

About ContraVir Pharmaceuticals (NASDAQ:CTRV)

ContraVir Pharmaceuticals logoContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted antiviral therapies with three candidates in the pipeline. Two of its antiviral candidates for treating hepatitis B include Phase IIa clinical candidate TXL, a novel potent analog of antiviral drug tenofovir and decreased systemic exposure, thereby potentially reducing renal and bone side effects; and CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against hepatitis B virus.

Receive CTRV News and Ratings via Email

Sign-up to receive the latest news and ratings for CTRV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:CTRV
CUSIPN/A
Phone+1-732-9024000

Debt

Debt-to-Equity RatioN/A
Current Ratio3.18%
Quick Ratio3.18%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.11 per share
Price / Book3.09

Profitability

Trailing EPS($0.24)
Net Income$-14,890,000.00
Net MarginsN/A
Return on Equity-386.59%
Return on Assets-97.30%

Miscellaneous

Employees21
Outstanding Shares78,280,000

ContraVir Pharmaceuticals (NASDAQ:CTRV) Frequently Asked Questions

What is ContraVir Pharmaceuticals' stock symbol?

ContraVir Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTRV."

How were ContraVir Pharmaceuticals' earnings last quarter?

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) announced its quarterly earnings data on Friday, May, 13th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.09. View ContraVir Pharmaceuticals' Earnings History.

When will ContraVir Pharmaceuticals make its next earnings announcement?

ContraVir Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, December, 18th 2017. View Earnings Estimates for ContraVir Pharmaceuticals.

Where is ContraVir Pharmaceuticals' stock going? Where will ContraVir Pharmaceuticals' stock price be in 2017?

2 equities research analysts have issued 1-year price objectives for ContraVir Pharmaceuticals' stock. Their predictions range from $4.00 to $4.00. On average, they anticipate ContraVir Pharmaceuticals' stock price to reach $4.00 in the next twelve months. View Analyst Ratings for ContraVir Pharmaceuticals.

Who are some of ContraVir Pharmaceuticals' key competitors?

Who are ContraVir Pharmaceuticals' key executives?

ContraVir Pharmaceuticals' management team includes the folowing people:

  • Gary S. Jacob Ph.D., Chairman of the Board (Age 70)
  • James E. Sapirstein, Chief Executive Officer, Director (Age 54)
  • John T. Cavan, Chief Financial Officer (Age 58)
  • Robert T. Foster Ph.D., Chief Scientific Officer (Age 58)
  • Theresa Matkovits, Senior Vice President—Drug Development (Age 49)
  • John Z. Sullivan-Bolyai, Chief Medical Officer (Age 67)
  • Tamar D. Howson, Director (Age 68)
  • Thomas H. Adams Jr. Ph.D., Independent Director (Age 74)
  • Timothy Block, Independent Director (Age 61)
  • John P. Brancaccio CPA, Independent Director (Age 69)

How do I buy ContraVir Pharmaceuticals stock?

Shares of ContraVir Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ContraVir Pharmaceuticals' stock price today?

One share of ContraVir Pharmaceuticals stock can currently be purchased for approximately $0.34.

How big of a company is ContraVir Pharmaceuticals?

ContraVir Pharmaceuticals has a market capitalization of $26.61 million. The biopharmaceutical company earns $-14,890,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. ContraVir Pharmaceuticals employs 21 workers across the globe.

How can I contact ContraVir Pharmaceuticals?

ContraVir Pharmaceuticals' mailing address is 399 Thornall St, EDISON, NJ 08837-2236, United States. The biopharmaceutical company can be reached via phone at +1-732-9024000 or via email at [email protected]


MarketBeat Community Rating for ContraVir Pharmaceuticals (CTRV)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  96 (Vote Outperform)
Underperform Votes:  34 (Vote Underperform)
Total Votes:  130
MarketBeat's community ratings are surveys of what our community members think about ContraVir Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ContraVir Pharmaceuticals (NASDAQ:CTRV) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.00$4.00$5.00$5.00
Price Target Upside: 548.30% upside548.30% upside843.40% upside233.33% upside

ContraVir Pharmaceuticals (NASDAQ:CTRV) Consensus Price Target History

Price Target History for ContraVir Pharmaceuticals (NASDAQ:CTRV)

ContraVir Pharmaceuticals (NASDAQ:CTRV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/30/2017Maxim GroupSet Price TargetBuy$4.00N/AView Rating Details
4/21/2017Noble FinancialReiterated RatingBuyHighView Rating Details
6/1/2016ING GroupInitiated CoveragePositiveN/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

ContraVir Pharmaceuticals (NASDAQ:CTRV) Earnings History and Estimates Chart

Earnings by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)

ContraVir Pharmaceuticals (NASDAQ CTRV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/18/2017        
5/13/2016Q3($0.23)($0.14)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

ContraVir Pharmaceuticals (NASDAQ:CTRV) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.41 EPS

Dividends

Dividend History for ContraVir Pharmaceuticals (NASDAQ:CTRV)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

ContraVir Pharmaceuticals (NASDAQ CTRV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 6.65%
Insider Trades by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Institutional Ownership by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)

ContraVir Pharmaceuticals (NASDAQ CTRV) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/20/2017John T CavanCFOBuy20,000$0.65$13,000.00View SEC Filing  
2/18/2016James SapirsteinCEOBuy10,000$1.00$10,000.00View SEC Filing  
11/23/2015James SapirsteinCEOBuy2,500$1.64$4,100.00View SEC Filing  
3/4/2014John P BrancaccioDirectorBuy4,393$1.49$6,545.57View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ContraVir Pharmaceuticals (NASDAQ CTRV) News Headlines

Source:
DateHeadline
Zacks: Analysts Set $4.50 Price Target for ContraVir Pharmaceuticals Inc (CTRV)Zacks: Analysts Set $4.50 Price Target for ContraVir Pharmaceuticals Inc (CTRV)
www.americanbankingnews.com - December 14 at 5:40 PM
ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until December 21ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until December 21
www.nasdaq.com - December 13 at 5:30 PM
ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until December 21, 2017ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until December 21, 2017
finance.yahoo.com - December 13 at 5:30 PM
ContraVir Pharmaceuticals (CTRV) vs. Its Rivals Head-To-Head SurveyContraVir Pharmaceuticals (CTRV) vs. Its Rivals Head-To-Head Survey
www.americanbankingnews.com - December 12 at 5:36 AM
Contrasting ContraVir Pharmaceuticals (CTRV) & The CompetitionContrasting ContraVir Pharmaceuticals (CTRV) & The Competition
www.americanbankingnews.com - December 4 at 11:26 PM
Is ContraVir Pharmaceuticals Inc (CTRV) Undervalued?Is ContraVir Pharmaceuticals Inc (CTRV) Undervalued?
finance.yahoo.com - December 4 at 5:20 PM
 ContraVir Pharmaceuticals Inc (CTRV) Given $4.50 Consensus Price Target by Brokerages ContraVir Pharmaceuticals Inc (CTRV) Given $4.50 Consensus Price Target by Brokerages
www.americanbankingnews.com - November 28 at 8:00 AM
ContraVir Pharmaceuticals (CTRV) versus Its Competitors Financial ReviewContraVir Pharmaceuticals (CTRV) versus Its Competitors Financial Review
www.americanbankingnews.com - November 23 at 9:16 PM
ContraVir Pharma (CTRV) Secures $1.6M Non-Dilutive Funding through New Jersey Technology Business Tax ... - StreetInsider.comContraVir Pharma (CTRV) Secures $1.6M Non-Dilutive Funding through New Jersey Technology Business Tax ... - StreetInsider.com
www.streetinsider.com - November 7 at 5:03 AM
ContraVir Pharma (CTRV) Secures $1.6M Non-Dilutive Funding through New Jersey Technology Business Tax Certificate Transfer ProgramContraVir Pharma (CTRV) Secures $1.6M Non-Dilutive Funding through New Jersey Technology Business Tax Certificate Transfer Program
www.streetinsider.com - November 6 at 6:56 PM
ContraVir Pharmaceuticals to Receive Non-Dilutive Funding through New Jersey Technology Business Tax Certificate Transfer (NOL) ProgramContraVir Pharmaceuticals to Receive Non-Dilutive Funding through New Jersey Technology Business Tax Certificate Transfer (NOL) Program
finance.yahoo.com - November 6 at 6:56 PM
ContraVir Pharmaceuticals (CTRV) Buy Rating Reiterated at Maxim GroupContraVir Pharmaceuticals' (CTRV) Buy Rating Reiterated at Maxim Group
www.americanbankingnews.com - October 30 at 2:41 PM
Technical Insights on Biotech Stocks -- Celsion, Corcept Therapeutics, ContraVir Pharma, and Neuralstem - PR Newswire (press release)Technical Insights on Biotech Stocks -- Celsion, Corcept Therapeutics, ContraVir Pharma, and Neuralstem - PR Newswire (press release)
www.prnewswire.com - October 27 at 5:42 AM
ContraVir Pharma (CTRV) Reports NIH Funded Study on Antiviral Activity of CRV431 - StreetInsider.comContraVir Pharma (CTRV) Reports NIH Funded Study on Antiviral Activity of CRV431 - StreetInsider.com
www.streetinsider.com - October 24 at 7:59 PM
ContraVir Pharmaceuticals Announces National Institutes of Health Funded Study on Antiviral Activity of CRV431ContraVir Pharmaceuticals Announces National Institutes of Health Funded Study on Antiviral Activity of CRV431
finance.yahoo.com - October 24 at 7:59 PM
ContraVir Pharma (CTRV) Commences Dosing of Renally-Impaired Patients in First US Trial with TXL - StreetInsider.comContraVir Pharma (CTRV) Commences Dosing of Renally-Impaired Patients in First US Trial with TXL - StreetInsider.com
www.streetinsider.com - October 21 at 12:10 AM
ContraVir Pharma (CTRV) Commences Dosing of Renally-Impaired Patients in First U.S. Trial with TXLContraVir Pharma (CTRV) Commences Dosing of Renally-Impaired Patients in First U.S. Trial with TXL
www.streetinsider.com - October 19 at 6:14 PM
ContraVir Pharmaceuticals Initiated Dosing of Renally-Impaired Patients in First U.S. Trial with TXL™ContraVir Pharmaceuticals Initiated Dosing of Renally-Impaired Patients in First U.S. Trial with TXL™
finance.yahoo.com - October 19 at 6:14 PM
ContraVir Pharmaceuticals Inc (CTRV) PT Set at $4.00 by Maxim GroupContraVir Pharmaceuticals Inc (CTRV) PT Set at $4.00 by Maxim Group
www.americanbankingnews.com - October 19 at 11:58 AM
ContraVir Pharma (CTRV) Reports Collaboration Agreement with Li Ka Shing Institute of Virology - StreetInsider.comContraVir Pharma (CTRV) Reports Collaboration Agreement with Li Ka Shing Institute of Virology - StreetInsider.com
www.streetinsider.com - October 17 at 11:28 PM
ContraVir Pharmaceuticals Announces Research Collaboration Agreement with Li Ka Shing Institute of VirologyContraVir Pharmaceuticals Announces Research Collaboration Agreement with Li Ka Shing Institute of Virology
finance.yahoo.com - October 17 at 6:26 PM
ContraVir Pharmaceuticals to Present Three Posters at AASLD 2017 and Participate in the Search for HBV / HDV Cure ... - GlobeNewswire (press release)ContraVir Pharmaceuticals to Present Three Posters at AASLD 2017 and Participate in the Search for HBV / HDV Cure ... - GlobeNewswire (press release)
globenewswire.com - October 13 at 4:28 AM
ContraVir Pharmaceuticals Inc (CTRV) Short Interest Down 37.4% in SeptemberContraVir Pharmaceuticals Inc (CTRV) Short Interest Down 37.4% in September
www.americanbankingnews.com - October 13 at 1:32 AM
ContraVir Pharmaceuticals to Present Three Posters at AASLD 2017 and Participate in the Search for HBV / HDV Cure Analyst DayContraVir Pharmaceuticals to Present Three Posters at AASLD 2017 and Participate in the Search for HBV / HDV Cure Analyst Day
finance.yahoo.com - October 12 at 6:26 PM
Comparing ContraVir Pharmaceuticals (CTRV) and NeuroDerm (NDRM)Comparing ContraVir Pharmaceuticals (CTRV) and NeuroDerm (NDRM)
www.americanbankingnews.com - October 11 at 6:22 PM
ContraVir Pharmaceuticals to Present at The MicroCap Conference 2017 - GlobeNewswire (press release)ContraVir Pharmaceuticals to Present at The MicroCap Conference 2017 - GlobeNewswire (press release)
globenewswire.com - October 3 at 5:32 PM
ContraVir Pharmaceuticals Inc (CTRV): How Does It Impact Your Portfolio?ContraVir Pharmaceuticals Inc (CTRV): How Does It Impact Your Portfolio?
finance.yahoo.com - October 3 at 6:33 AM
ContraVir Pharmaceuticals to Present at The MicroCap Conference 2017ContraVir Pharmaceuticals to Present at The MicroCap Conference 2017
finance.yahoo.com - October 3 at 6:33 AM
Achillion Shares Are Plunging on Termination of Hepatitis C Pact - TheStreet.comAchillion Shares Are Plunging on Termination of Hepatitis C Pact - TheStreet.com
www.thestreet.com - September 12 at 6:20 PM
ContraVir Pharmaceuticals Receives HBV IND Approval for Tenofovir Exalidex (TXL™) in the United States - GlobeNewswire (press release)ContraVir Pharmaceuticals Receives HBV IND Approval for Tenofovir Exalidex (TXL™) in the United States - GlobeNewswire (press release)
globenewswire.com - September 12 at 6:20 PM
ContraVir Pharma (CTRV) Reports Acceptance of Clinical Trial Application in the UK, - StreetInsider.comContraVir Pharma (CTRV) Reports Acceptance of Clinical Trial Application in the UK, - StreetInsider.com
www.streetinsider.com - September 7 at 3:40 AM
ContraVir Pharmaceuticals Announces Acceptance of Clinical Trial Application in the United KingdomContraVir Pharmaceuticals Announces Acceptance of Clinical Trial Application in the United Kingdom
finance.yahoo.com - September 6 at 5:37 PM
ContraVir Pharmaceuticals Announces Participation at the 19th Annual Rodman & Renshaw Global Investment ... - GlobeNewswire (press release)ContraVir Pharmaceuticals Announces Participation at the 19th Annual Rodman & Renshaw Global Investment ... - GlobeNewswire (press release)
globenewswire.com - September 6 at 12:14 AM
ContraVir Pharmaceuticals Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017ContraVir Pharmaceuticals Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017
finance.yahoo.com - September 5 at 7:11 PM
ContraVir Pharmaceuticals Inc (CTRV) Given a $4.00 Price Target at Maxim GroupContraVir Pharmaceuticals Inc (CTRV) Given a $4.00 Price Target at Maxim Group
www.americanbankingnews.com - August 24 at 3:22 PM
ContraVir Pharmaceuticals Announces Issuance of New US Patent for Expansion of Cyclophilin Inhibitor Program - GlobeNewswire (press release)ContraVir Pharmaceuticals Announces Issuance of New US Patent for Expansion of Cyclophilin Inhibitor Program - GlobeNewswire (press release)
globenewswire.com - August 22 at 11:14 PM
ContraVir Pharma (CTRV) Granted U.S. Patent for Expansion of Cyclophilin Inhibitor ProgramContraVir Pharma (CTRV) Granted U.S. Patent for Expansion of Cyclophilin Inhibitor Program
www.streetinsider.com - August 21 at 5:21 PM
ContraVir Pharmaceuticals Selected to Present Poster on TXL™ at the Upcoming AASLD Meeting® 2017ContraVir Pharmaceuticals Selected to Present Poster on TXL™ at the Upcoming AASLD Meeting® 2017
www.nasdaq.com - August 9 at 3:24 AM
ContraVir Pharmaceuticals Selected to Present Poster on TXL™ at the Upcoming AASLD Meeting® 2017 - GlobeNewswire (press release)ContraVir Pharmaceuticals Selected to Present Poster on TXL™ at the Upcoming AASLD Meeting® 2017 - GlobeNewswire (press release)
globenewswire.com - August 8 at 5:22 PM
ContraVir Pharmaceuticals Selected to Present Poster on TXL™ at the Upcoming AASLD Meeting® 2017ContraVir Pharmaceuticals Selected to Present Poster on TXL™ at the Upcoming AASLD Meeting® 2017
finance.yahoo.com - August 8 at 5:22 PM
ContraVir Pharmaceuticals Selected to Present Two Posters on CRV431 at the Upcoming AASLD Meeting® 2017 - NasdaqContraVir Pharmaceuticals Selected to Present Two Posters on CRV431 at the Upcoming AASLD Meeting® 2017 - Nasdaq
www.nasdaq.com - August 4 at 5:53 PM
ContraVir Pharmaceuticals Selected to Present Two Posters on CRV431 at the Upcoming AASLD Meeting® 2017ContraVir Pharmaceuticals Selected to Present Two Posters on CRV431 at the Upcoming AASLD Meeting® 2017
finance.yahoo.com - August 3 at 7:00 PM
 Analysts Expect ContraVir Pharmaceuticals Inc (CTRV) Will Post Earnings of -$0.09 Per Share Analysts Expect ContraVir Pharmaceuticals Inc (CTRV) Will Post Earnings of -$0.09 Per Share
www.americanbankingnews.com - July 5 at 12:34 PM
ContraVir Pharma (CTRV) to Advance Second-Generation Formulation of TXL for Treatment of HBV - StreetInsider.comContraVir Pharma (CTRV) to Advance Second-Generation Formulation of TXL for Treatment of HBV - StreetInsider.com
www.streetinsider.com - May 6 at 7:58 AM
Mid-Day Market Update: NASDAQ Hits 6,000; Heidrick & Struggles Shares Drop On Downbeat ResultsMid-Day Market Update: NASDAQ Hits 6,000; Heidrick & Struggles Shares Drop On Downbeat Results
www.nasdaq.com - April 25 at 4:20 PM
ContraVir Pharma (CTRV) Presents Data on Complementary Anti-HBV Compounds Tenofovir Exalidex (TXL) & CRV431ContraVir Pharma (CTRV) Presents Data on Complementary Anti-HBV Compounds Tenofovir Exalidex (TXL) & CRV431
www.streetinsider.com - April 24 at 9:15 AM
ContraVir’s Cyclophilin Inhibitor CRV431 Targets Hepatitis B Surface Antigen (HBsAg)ContraVir’s Cyclophilin Inhibitor CRV431 Targets Hepatitis B Surface Antigen (HBsAg)
www.nasdaq.com - April 4 at 8:49 AM
CONTRAVIR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportCONTRAVIR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - February 14 at 8:46 PM
ContraVir Pharmaceuticals to Present at BIO CEO & Investor Conference - PR Newswire (press release)ContraVir Pharmaceuticals to Present at BIO CEO & Investor Conference - PR Newswire (press release)
www.prnewswire.com - February 7 at 10:44 PM
Technical Reports on Biotech Stocks -- ContraVir Pharma, Arena Pharma, Neuralstem, and CTI BioPharmaTechnical Reports on Biotech Stocks -- ContraVir Pharma, Arena Pharma, Neuralstem, and CTI BioPharma
www.bizjournals.com - January 17 at 5:25 PM

SEC Filings

ContraVir Pharmaceuticals (NASDAQ:CTRV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ContraVir Pharmaceuticals (NASDAQ:CTRV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ContraVir Pharmaceuticals (NASDAQ CTRV) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.